Annual report [Section 13 and 15(d), not S-K Item 405]

Stock-Based Compensation (Tables)

v3.26.1
Stock-Based Compensation (Tables)
12 Months Ended
Dec. 31, 2025
Share-Based Payment Arrangement [Abstract]  
Schedule of Restricted Stock Unit Activity

A summary of our restricted stock unit activity is set forth below:
 

 

Shares

 

 

Weighted Average Grant Date Fair Value

 

Outstanding as of December 31, 2024

 

 

38,420

 

 

$

23.01

 

Granted

 

 

-

 

 

 

-

 

Released

 

 

(17,415

)

 

 

26.48

 

Forfeited

 

 

(3,273

)

 

 

14.43

 

Outstanding as of December 31, 2025

 

 

17,732

 

 

$

21.17

 

 

During 2024, we granted 84,089 restricted stock units to board members and external consultants with an average grant date fair value of $5.63. Each of the restricted stock unit grants vested immediately. The restricted stock unit grants were valued based on the fair value of our common stock on the date of grant.

Schedule of Stock Option Activity

A summary of our stock option activity under the 2018 Plan and related information is as follows:
 

 

Number of Shares

 

 

Weighted Average
Exercise Price

 

 

Weighted Average
Remaining
Contractual Term
(years)

 

 

Aggregate Intrinsic
Value

 

Outstanding as of December 31, 2024

 

 

2,500

 

 

$

56.89

 

 

 

3.19

 

 

$

-

 

Granted

 

 

-

 

 

 

-

 

 

 

 

 

 

 

Exercised

 

 

-

 

 

 

-

 

 

 

 

 

 

 

Cancelled/Expired

 

 

(1,500

)

 

 

38.15

 

 

 

 

 

 

 

Outstanding and exercisable as of December 31, 2025

 

 

1,000

 

 

$

85.00

 

 

 

6.61

 

 

$

-

 

 

A summary of our stock option activity under the 2009 Plan and related information is set forth below:
 

 

Number of Shares

 

 

Weighted Average Exercise Price

 

 

Weighted Average Remaining
Contractual Term (years)

 

 

Aggregate Intrinsic Value

 

Outstanding as of December 31, 2024

 

 

1,190

 

 

$

91.61

 

 

 

2.50

 

 

$

-

 

Granted

 

 

-

 

 

 

-

 

 

 

 

 

 

 

Exercised

 

 

-

 

 

 

-

 

 

 

 

 

 

 

Cancelled/Expired

 

 

(307

)

 

 

28.48

 

 

 

 

 

 

 

Outstanding and exercisable as of December 31, 2025

 

 

883

 

 

$

113.56

 

 

 

2.24

 

 

$

-

 

Schedule of Stock-Based Compensation

Compensation cost that has been included in our consolidated statements of operations and comprehensive loss for all stock-based compensation arrangements is set forth below:
 

 

Year ended December 31,

 

(in thousands)

 

2025

 

 

2024

 

Cost of revenues

 

$

62

 

 

$

179

 

Sales and marketing

 

 

34

 

 

 

65

 

General and administrative

 

 

351

 

 

 

1,341

 

Research and development

 

 

8

 

 

 

71

 

Total stock-based compensation

 

$

455

 

 

$

1,656